Dr. McCullough Not Recommending Fall Vaccines for Healthy Adults and Children

Products are Not Compelling for Prevention of Severe COVID-19, Influenza, RSV

Peter McCullough, MD Oct 20

READ IN APP

By Peter A. McCullough, MD, MPH

I appeared on American Sunrise (10/18/23) with Dr. Gina Loudon to let America know I am not recommending COVID-19 XBB.1.5 Boosters, influenza, or respiratory syncytial virus vaccines for healthy adults or children. None of these vaccines are compelling and conditions are easily treatable. The EUA COVID-19 injections have been determined to be unsafe for human use by the World Council for Health and the Association of American Physicians and Surgeons.

None of these vaccines have compelling efficacy. For example, the RENOIR Trial in 34,284 adults tested the unadjuvanted RSVpreF vaccine at a dose of 120 μg (containing 60 μg each of RSV A and RSV B antigens) (17,215 participants) versus placebo (17,069 participants). RSV-associated lower respiratory tract illness with at least two signs or symptoms occurred in 11 participants in the vaccine group and 33 participants in the placebo group, (vaccine efficacy, 66.7%; 96.66% confidence interval

[CI], 28.8 to 85.8); 2 cases and 14 cases with least three signs or symptoms (vaccine efficacy, 85.7%; 96.66% CI, 32.0 to 98.7). RSV-associated acute respiratory illness occurred in 22 participants in the vaccine group and 58 participants in the placebo group, vaccine efficacy, 62.1%; 95% CI, 37.1 to 77.9). There were no hospitalizations or deaths mentioned in either group. Because data are sparse, we must rely on the lower limit of the confidence interval for treatment effect, which is unacceptable being far below 50% for all outcomes.

RSV, like influenza and COVID-19 are easily treatable infections at home. As you can see RSV is very rare with <1% of adults contracting the virus. Vaccinating the entire adult population is an excessive use of a poorly effective new product. For healthy persons, it is perfectly reasonable to skip fall vaccines and seek early treatment in the rare circumstance that one of these viral infections is contracted.

Please subscribe to Courageous Discourse as a paying or founder member so we can continue to bring you the truth.

Courageous Discourse™ with Dr. Peter McCullough & John Leake is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Upgrade to paid

Peter A. McCullough, MD, MPH

President, McCullough Foundation

www.mcculloughfnd.org

Like Comment Restack

Originally posted on

Courageous Discourse™ with Dr. Peter McCullough & John LeakePeter McCullough, MD Subscribe

Advancement of clinical science, protection of personal autonomy, liberty, and constitutional rights.

© 2023 Paul Thomas MD
3515 SW 108th ave. Beaverton, Oregon 97005
Unsubscribe

Paul Thomas MD (retired)Oct 20 · Paul’s Substack

I agree 100% with Dr McCullough's assessment here. RSV in infants: I just learned this morning about a baby hospitalized for RSV who had 8 days of fever and oxygen saturations that were in the high 80's - 93% on room air at home. The infant was brought in to be seen, looked grey at times and oxygen was in the low 80's. Thankfully this baby was hospitalized and in addition to RSV they found on CXR an upper lobe pneumonia, which suggests a bacterial infection in addition to the RSV. Note that unlike adult COVID hypoxia, where adults could tolerate oxygen in the low 80's, infants cannot tolerate this for long and along with an untreated bacterial infection (persistent fever a clue) these infants need both oxygen and appropriate antibiotics. Dr. Paul Thomas (retired pediatrician)